SUMF1 and central nervous system cancer: For glioma with the IDH mutation, 1p/19q codeletion (codel or non-codel), gender (female or male), age (>60 or ≤60), and type of glioma (astrocytoma or oligodendroglioma), a significant correlation was observed between the overexpression of SUMF1 and adverse survival outcomes in patients (Figure 3).